DiappyMed's goal is to lead Type 1 diabetes patients towards a more effective treatment, autonomy and empowerment by providing them with the first clinically validated mobile app for intelligent insulin dosing. Relying heavily on data science, new technologies and artificial intelligence, we aim to equip insulin-dependent patients with an all-in-one solution that will provide them with an easy-to-get and personalized insulin dose recommendation. Their first clinical trials show an improvement of patient’s blood glucose level control (time in range). The company is supported by:- Montpellier University Hospital’s Innovation Extractor- IMT Mines Alès Incubator- Montpellier BIC - University of Montpellier- Occitanie RegionWe are also in the process of building and consolidating partnerships with renowned research laboratories to work on various artificial intelligence technologies.